Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02602795
Recruitment Status : Completed
First Posted : November 11, 2015
Last Update Posted : August 29, 2018
Sponsor:
Information provided by (Responsible Party):
Rhode Island Hospital

Brief Summary:
Before starting treatment with XR-NTX, a medication that blocks the positive effects of opioids and helps people stay off opioids, individuals who are dependent on opioids first have to endure a difficult withdrawal process. This study aims to develop and test an intervention to help people who are opioid dependent successfully complete that transition; the investigators will also develop and test a comparison condition aimed at reducing HIV risk behavior.

Condition or disease Intervention/treatment Phase
Opiate Dependence Sexually Transmitted Diseases HIV Behavioral: Acceptance and Commitment Therapy Behavioral: Information Motivation Behavioral Model Not Applicable

Detailed Description:

Opioid dependence is a serious and increasingly pervasive problem. Opioid dependent individuals are at significantly increased risk for a wide range of physical and psychological problems including HIV and STIs. Extended-release naltrexone (XR-NTX) is an effective treatment for opioid dependence, but it requires that opioid-dependent individuals be completely opioid-free prior to its initiation to avoid precipitated withdrawal. The great majority of individuals attempting to cease opioid use will relapse before initiation of XR-NTX because of opioid withdrawal symptoms during detoxification. Distress Tolerance (DT) focused psychosocial interventions are well suited to address the clinical phenomena experienced by individuals withdrawing from opioids.

The purpose of this project is to develop a DT intervention to improve detoxification outcomes and an active comparison intervention targeting HIV and STI (HIV/STI) risk behavior. The DT intervention will be adapted from Acceptance and Commitment Therapy (ACT). The HIV/STI risk behavior intervention will target behaviors that put patients at risk for HIV and STIs including unprotected sex and needle sharing, as well as promoting regular HIV testing. Both interventions will be delivered through a telehealth videoconferencing system. If the HIV/STI intervention is found to result in reduced HIV/STI risk behavior and more frequent HIV testing, relative to the DT intervention, the investigators will incorporate its components into the DT intervention prior to launching a large-scale clinical trial. The long-term objective of this research program is to improve substance use and HIV/STI outcomes for opioid dependent individuals attempting to cease opioid use.

In Phase 1 of this project, the investigators will develop and pilot a DT intervention for individuals transitioning to XR-NTX and a time-matched HIV/STI risk reduction comparison intervention; both will be developed using an iterative process of piloting and modification based on data collected from pilot participants. In Phase 2, opioid dependent individuals transitioning to XR-NTX will be randomly assigned to DT, HIV/STI, or Treatment-As-Usual. All patients will receive medication assisted detoxification from the study recruitment site. It is expected that, as a result of this project, the investigators will have developed a well-specified and novel DT intervention tailored to meet the needs of opioid dependent patients transitioning to XR-NTX, the efficacy of which can be further tested in future Stage II randomized controlled trials. If found to be efficacious, this intervention will serve as an effective means of facilitating detoxification and opioid antagonist initiation, reducing the individual and societal burden due to opioid dependence.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence
Study Start Date : December 2015
Actual Primary Completion Date : January 2018
Actual Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Distress Tolerance (DT)
Acceptance and Commitment Therapy based Distress Tolerance (DT) intervention to facilitate opioid detoxification delivered in six 50-minute individual telehealth sessions.
Behavioral: Acceptance and Commitment Therapy
The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.

Active Comparator: HIV/STI Intervention
Information Motivation Behavioral model based HIV/STI risk reduction intervention delivered in six 50-minute individual telehealth sessions.
Behavioral: Information Motivation Behavioral Model
This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.

No Intervention: Treatment As Usual (TAU)
Traditional treatment given to patients who elect to transition to XR-NTX at the treatment sites.



Primary Outcome Measures :
  1. Successful Detoxification [ Time Frame: 6-months ]
    The investigators will compare the odds of successful detoxification, or receipt of the first XR-NTX injection, between treatment groups.

  2. Number of XR-NTX Injections Received [ Time Frame: 6-months ]
    The treatment groups will be compared on the number of XR-NTX injections received during follow-up.

  3. Opioid Drug Use Outcomes [ Time Frame: 6-months ]
    Percent of opioid use days compared between the groups

  4. Illicit Drug Use Outcomes [ Time Frame: 6-months ]
    Percent of illicit drug use days compared between the groups


Secondary Outcome Measures :
  1. Sex Risk Behavior [ Time Frame: 6-months ]
    The investigators will compare the occurrence of sex risk behavior between the treatment groups.

  2. Drug Risk Behavior [ Time Frame: 6-months ]
    The investigators will compare the occurrence of drug risk behavior between the treatment groups.

  3. HIV Risk Behavior [ Time Frame: 6-months ]
    The investigators will compare the occurrence of overall HIV risk behavior between the treatment groups.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must (1) meet Diagnostic and Statistical Manual of Mental Disorders-IV Lifetime criteria for Opioid Dependence, (2) not plan to receive opioid agonist treatment or opioid analgesics, (3) have no medical need for opioid pain medication, (4) have Alanine Transaminase and Aspartate Aminotransferase < 150, and (5) have platelets > 90.

Exclusion Criteria:

  • Must not (1) be currently psychotic, (2) have current drug or alcohol dependence that requires medical detoxification or a higher level of care that would interfere with study participation, (3) be pregnant or lactating, (4) have acute hepatitis or liver failure, (5) have a bleeding disorder, or (6) be allergic to XR-NTX components.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02602795


Locations
Layout table for location information
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Rhode Island Hospital
Investigators
Layout table for investigator information
Principal Investigator: Susan E Ramsey, Ph.D. Rhode Island Hospital

Layout table for additonal information
Responsible Party: Rhode Island Hospital
ClinicalTrials.gov Identifier: NCT02602795     History of Changes
Other Study ID Numbers: R34DA037797 ( U.S. NIH Grant/Contract )
First Posted: November 11, 2015    Key Record Dates
Last Update Posted: August 29, 2018
Last Verified: April 2017

Keywords provided by Rhode Island Hospital:
Opiate Dependence
Sexually Transmitted Diseases
HIV
Extended release naltrexone

Additional relevant MeSH terms:
Layout table for MeSH terms
Opioid-Related Disorders
Sexually Transmitted Diseases
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Infection
Virus Diseases
Genital Diseases, Male
Genital Diseases, Female
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents